BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 24720402)

  • 1. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
    Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride.
    Gen S; Sasaki T; Saito K; Nobe K; Nodaira Y; Ikeda N
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():8-12. PubMed ID: 24975889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of hyperphosphatemia with bixalomer in Japanese hemodialysis patients.
    Akizawa T; Kameoka C; Kaneko Y; Kawasaki S;
    Ther Apher Dial; 2013 Dec; 17(6):612-9. PubMed ID: 24330556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms.
    Ito K; Takeshima A; Shishido K; Wakasa M; Kumata C; Matsuzaka K; Nakajima Y; Ogata H
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():19-23. PubMed ID: 24975891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of switching from sevelamer hydrochloride to bixalomer on laboratory parameters in hemodialysis patients.
    Furukawa K; Ikawa T; Yokoi S; Yokouchi S; Kato K; Ueno M; Takahashi J
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():2-7. PubMed ID: 24975888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
    Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
    Taniguchi K; Kakuta H
    Eur J Pharmacol; 2015 Nov; 766():129-34. PubMed ID: 26452517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experiences of bixalomer usage at our hospital.
    Shima H; Makino R; Hata K; Ban A; Funao K; Sugita S; Furumitsu Y; Inoue K; Yoshimoto M; Okamura M
    Ther Apher Dial; 2014 Jun; 18 Suppl 2():13-8. PubMed ID: 24975890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
    Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
    Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis: Phase 3 Randomized Trial.
    Akizawa T; Origasa H; Kameoka C; Tsukada J; Kuroishi K; Yamaguchi Y
    Ther Apher Dial; 2016 Dec; 20(6):588-597. PubMed ID: 27896908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis.
    Hatakeyama S; Murasawa H; Narita T; Oikawa M; Fujita N; Iwamura H; Mikami J; Kojima Y; Sato T; Fukushi K; Ishibashi Y; Hashimoto Y; Koie T; Saitoh H; Funyu T; Ohyama C
    BMC Nephrol; 2013 Oct; 14():222. PubMed ID: 24119202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
    Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
    Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
    Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
    Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Safety and Efficacy of Bixalomer in Hyperphosphatemic Patients With Chronic Kidney Disease Not on Dialysis.
    Akizawa T; Tsukada J; Kameoka C; Kuroishi K; Yamaguchi Y
    Ther Apher Dial; 2017 Apr; 21(2):173-179. PubMed ID: 28194884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications.
    Pai AB; Shepler BM
    Pharmacotherapy; 2009 May; 29(5):554-61. PubMed ID: 19397463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of SBR759, a novel calcium-free, iron(III)-based phosphate binder, in Asian patients undergoing hemodialysis: A 12-week, randomized, open-label, dose-titration study versus sevelamer hydrochloride.
    Chen JB; Chiang SS; Chen HC; Obayashi S; Nagasawa M; Hexham JM; Balfour A; Junge G; Akiba T; Fukagawa M
    Nephrology (Carlton); 2011 Nov; 16(8):743-50. PubMed ID: 21854503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
    Senatore M; Coppolino G; Papalia T; Greco R; Lofaro D; Bonofiglio R
    Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1352-4. PubMed ID: 22195373
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.